|Videos|June 29, 2016

What do Healthcare Providers Need to Know About the Pennsylvania Superbug Infection?

Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, president, Society of Infectious Diseases Pharmacists, explains what healthcare providers need to know about this most recent case of a superbug infection in the US.

Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, president, Society of Infectious Diseases Pharmacists, explains what healthcare providers need to know about this most recent case of a superbug infection in the US.

Interview Transcript (slightly modified for readability)

“So the most important thing for a healthcare provider to know about this case is that this resistance is here in the United States, but it may or may not be isolated, we really don’t know.

Because colistin testing is not routinely done for [Escherichia] coli, we have absolutely no idea how many isolates are resistant and how many are susceptible. It’s very likely that a very low percentage is resistant. [I'm sure] that this is not the only case in the country, it’s just the only one that we have found.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.